monkey |
LD50 |
oral |
> 4gm/kg (4000mg/kg) |
|
Cardiovascular Drug Reviews. Vol. 8, Pg. 1, 1990. |
mouse |
LD50 |
intraperitoneal |
1300mg/kg (1300mg/kg) |
|
Cardiovascular Drug Reviews. Vol. 8, Pg. 1, 1990. |
mouse |
LD50 |
intravenous |
> 30mg/kg (30mg/kg) |
|
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17, Pg. 1281, 1989. |
mouse |
LD50 |
subcutaneous |
> 1gm/kg (1000mg/kg) |
skin and appendages (skin): "dermatitis, other: after systemic exposure" skin and appendages (skin): hair: other
|
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17, Pg. 1281, 1989. |
mouse |
LDLo |
oral |
5gm/kg (5000mg/kg) |
behavioral: altered sleep time (including change in righting reflex) behavioral: convulsions or effect on seizure threshold
|
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17, Pg. 1281, 1989. |
rat |
LD50 |
intraperitoneal |
830mg/kg (830mg/kg) |
|
Cardiovascular Drug Reviews. Vol. 8, Pg. 1, 1990. |
rat |
LD50 |
intravenous |
> 30mg/kg (30mg/kg) |
|
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17, Pg. 1281, 1989. |
rat |
LD50 |
oral |
> 5gm/kg (5000mg/kg) |
gastrointestinal: changes in structure or function of salivary glands gastrointestinal: "hypermotility, diarrhea"
|
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17, Pg. 1281, 1989. |
rat |
LD50 |
subcutaneous |
> 1gm/kg (1000mg/kg) |
skin and appendages (skin): "dermatitis, other: after systemic exposure" behavioral: regidity
|
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17, Pg. 1281, 1989. |
women |
TDLo |
oral |
15mg/kg/22W-I (15mg/kg) |
skin and appendages (skin): "dermatitis, other: after systemic exposure"
|
Lancet. Vol. 345, Pg. 398, 1995. |